Reshma Shringarpure

Reshma Shringarpure is Vice President of Clinical Research and Medical Affairs at Akero. She brings over 15 years of experience in clinical and medical affairs across multiple therapeutic areas including GI, non-viral liver disease, and metabolic disease. Reshma joins Akero from Intercept Pharmaceuticals, where she was the clinical lead for the company’s late-stage NASH program and was integral to achieving several company milestones towards registrational filings in the US and Europe. Prior to joining Intercept, she was the director of medical affairs at Santarus, which was subsequently acquired by Salix Pharmaceuticals. Leading up to this role, Reshma held several scientific positions at Prometheus Therapeutics and Diagnostics as the clinical and medical affairs lead focused on Prometheus’ GI portfolio. She started her pharmaceutical career at Amylin Pharmaceuticals focusing on metabolic diseases and is a co-author of several peer-reviewed publications. Reshma holds a Ph.D. in Molecular Biology from the University of Southern California and completed her post-doctoral training at Dana Farber Cancer Institute, Harvard Medical School.